|
2024
|
Invention
|
Heterodimeric antibodies that bind cd3 and cldn6.
Provided herein are novel CLDN6 binding domain... |
|
|
Invention
|
Fc variants with altered binding to fcrn.
The present application relates to a variant Fc region... |
|
|
Invention
|
Heterodimeric antibodies that bind msln and cd3.
The present invention is directed to antibodies... |
|
|
Invention
|
Orthogonal multimeric proteins.
Provided herein are multimeric proteins that reduce the promiscu... |
|
|
Invention
|
Orthogonal multimeric proteins. Provided herein are multimeric proteins that reduce the promiscuo... |
|
|
Invention
|
Anti-cd28 x anti-trop2 antibodies. Provided herein are novel anti-CD28 x anti-TROP2 antibodies an... |
|
|
Invention
|
Anti-cd28 x anti-enpp3 antibodies. Provided herein are novel anti-CD28 x anti-ENPP3 antibodies an... |
|
|
Invention
|
Anti-cd28 compositions. Provided herein are novel anti-CD28 x anti-STEAPl and anti-CD28 x anti-CE... |
|
|
Invention
|
Anti-steap1 antigen-binding protein.
The disclosure provides novel antigen-binding proteins that... |
|
|
Invention
|
Anti-cd28 x anti-psma antibodies.
Provided herein are novel anti-CD28 x anti-PSMA antibodies and... |
|
|
Invention
|
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment ... |
|
|
Invention
|
Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers.
The presen... |
|
|
Invention
|
Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties.
The present inventi... |
|
|
Invention
|
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3.
Provided h... |
|
|
Invention
|
Complement component c5 antibodies.
The present disclosure relates to antibodies and polynucleot... |
|
2023
|
Invention
|
Il18-fc fusion proteins.
Provided herein are variant human IL18 proteins including proteins and ... |
|
|
Invention
|
Il-18-fc fusion proteins. Provided herein are variant human IL18 proteins including proteins and ... |
|
|
Invention
|
Bispecific antibodies that bind to b7h3 and mica/b. Provided herein are anti-MICA/B × anti-B7H3 a... |
|
|
Invention
|
Combination treatment with a bispecific antibody that binds ctla4 and pd1 for prostate cancer. Pr... |
|
|
Invention
|
Natural killer cell antibodies with increased adcc activity.
Described herein are antibodies, in... |
|
|
P/S
|
Biochemicals, namely, antibodies and fragments thereof for
research and development; biochemical... |
|
|
P/S
|
Biochemicals, namely, antibodies and fragments thereof for research and development; biochemicals... |
|
|
Invention
|
Heterodimeric proteins.
In one aspect, the present invention provides heterodimeric antibodies c... |
|
|
Invention
|
An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic der... |
|
|
Invention
|
Optimized fc variants.
The present invention relates to Fc variants having decreased affinity fo... |
|
|
Invention
|
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors.
The pre... |
|
|
Invention
|
Heterodimeric antibodies that bind cd3 and gpc3.
Provided herein are novel GPC3 binding domains,... |
|
|
Invention
|
Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and fcrh5xcd3 bispecific antibo... |
|
|
Invention
|
Bispecific binding agents binding to cldn18.2 and cd3.
The present invention provides binding ag... |
|
|
Invention
|
Optimized antibody variable regions.
The present invention is directed to optimized anti-CD3 var... |
|
|
Invention
|
Methods for treating solid tumors using icos x pd-1 bispecific antibodies. Provided herein, in ce... |
|
|
Invention
|
Anti-cd28 x anti-psma antibodies.
Provided herein are novel anti-CD28×anti-PSMA antibodies and m... |
|
|
Invention
|
Heterodimeric antibodies that bind cd3 and tumor antigens.
The present invention is directed to ... |
|
|
Invention
|
Antibodies that bind pd-l1, pd-l2, and/or cd28.
Provided herein are novel αPD-L1, αPD-L2, and αC... |
|
|
Invention
|
Antibodies that bind pd-l1, pd-l2 and/or cd28. Provided herein are novel aPD-Ll, aPD-L2, and aCD2... |
|
|
Invention
|
Methods for treating lymphoma. Provided herein, in certain aspects, are methods for the treatment... |
|
|
Invention
|
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-... |
|
|
Invention
|
Novel heterodimeric proteins.
The invention provides novel heterodimeric proteins including hete... |
|
|
Invention
|
Anti-cd28 x anti-trop2 antibodies.
Provided herein are novel anti-CD28 x anti-TROP2 antibodies a... |
|
|
Invention
|
Anti-cd28 x anti-msln antibodies.
Provided herein are novel anti-CD28×anti-MSLN antibodies and m... |
|
|
Invention
|
Anti-cd28 x anti-msln antibodies. Provided herein are novel anti-CD28 x anti-MSLN antibodies and ... |
|
|
Invention
|
Optimized antibodies that target cd19.
The present invention describes antibodies that target CD... |
|
2022
|
Invention
|
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding doma... |
|
|
Invention
|
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-... |
|
|
Invention
|
B-cell maturation antigen (bcma) binding domain compositions.
Provided herein are novel BCMA bin... |
|
|
Invention
|
Anti-tslpr (crlf2) antibodies.
The present disclosure provides antibodies and antigen-binding do... |
|
|
Invention
|
Heterodimeric antibodies that bind claudin18.2 and cd3.
The present invention is directed to ant... |
|
2021
|
Invention
|
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus er... |
|
2018
|
P/S
|
pharmaceuticals, namely, antibodies and proteins for the treatment of oncological and autoimmune ... |
|
2004
|
P/S
|
Chemicals used in industry and science; enzymes and reagents for scientific, industrial, agricult... |
|
|
P/S
|
Pharmaceutical preparations for biological response modifier therapy, anti-cancer therapy, and ch... |
|
2003
|
P/S
|
Biochemicals, namely, monoclonal antibodies and fragments thereof for research and development, f... |
|
|
P/S
|
Pharmaceuticals, namely, monoclonal antibodies and fragments thereof for therapeutic use for the ... |
|
2002
|
P/S
|
Pharmaceutical preparations for hormone replacement therapies, cancer gene therapy, diabetes ther... |
|
|
P/S
|
Biotechnological products, being industrial enzymes and proteins, including pulp and paper proces... |
|
1998
|
P/S
|
PHARMACEUTICAL PREPARATIONS FOR [ HORMONE REPLACEMENT THERAPIES, CANCER GENE THERAPY, DIABETES TH... |
|
|
P/S
|
Biotechnological products for medical or veterinary purposes, being pulp and paper processing enz... |
|
|
P/S
|
computer programming services for automated molecular design and biotechnology and pharmaceutical... |
